ANHL1131: Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma (NHL) or Mature B-cell Leukemia (B-AL): Evaluation of Rituximab Efficacy and Safety in High Risk Patients

Service: Trial Number:
081-12
Principal Investigator: Conducted at:
Miller Children`s & Women`s Hospital Long Beach
Currently enrolling additional patients:
Yes
Age Range:
6 months to less than 18 years of age
Gender:
Male & Female

Primary Mediastinal Large B-Cell Lymphoma (PMBCL) is an uncommon type of non Hodgkin’s lymphoma in children. PMBCL is more difficult to cure in children than other types of B cell lymphomas. Recent studies in adults have shown very promising results with the combination of a drug called rituximab with a chemotherapy regimen known as DA-EPOCH. Using rituximab with DA-EPOCH has not been studied in the children or adolescents. This study is being done to find out what effects (good and/or bad) using rituximab in combination with the DA-EPOCH chemotherapy regimen will have on children with PMLBL. We also want to find out if this new approach can improve the treatment success of children with PMLBL.